Drug Profile
Research programme: inflammation therapy - AstraZeneca
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator AstraZeneca; Cambridge Antibody Technology
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (Injection)
- 15 Feb 2008 Research is ongoing in Respiratory disorders and Inflammation
- 15 Feb 2008 This programme is available for partnering (http://www.astrazeneca.com/)